ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB plus DOCETAXEL FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER AGAINST TREATMENT WITH TRASTUZUMAB plus DOCETAXEL plus PLACEBO, IN THE VENEZUELAN CONTEXT

被引：0
|
作者：
Romero, M. [1 ]
Huerfano, L. M. [2 ]
Acero, G. [1 ]
机构：
[1] Salutia Fdn, Bogota, Colombia
[2] Salutia Fdn, Res Ctr Econ Management & Hlth Technol, Bogota, Colombia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN41
引用
收藏
页码：A822 / A822
页数：1
相关论文
共 50 条
  • [1] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    BREAST CANCER RESEARCH, 2017, 19
  • [2] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    Breast Cancer Research, 19
  • [3] Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
    Arrondeau, Jennifer
    Cottu, P.
    ONCOLOGIE, 2012, 14 (05) : 351 - 352
  • [4] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    Baselga, Jose
    Cortes, Javier
    Kim, Sung-Bae
    Im, Seock-Ah
    Hegg, Roberto
    Im, Young-Hyuck
    Roman, Laslo
    Pedrini, Jose Luiz
    Pienkowski, Tadeusz
    Knott, Adam
    Clark, Emma
    Benyunes, Mark C.
    Ross, Graham
    Swain, Sandra M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02): : 109 - 119
  • [5] Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
    Ewer, Michael
    Baselga, Jose
    Clark, Emma
    Benyunes, Mark
    Ross, Graham
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yamashita, Yuji
    Tanaka, Yuko
    Nishimura, Meiko
    Mukohara, Toru
    Kono, Seishi
    Takao, Shintaro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [7] Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence
    Demonty, Gaston
    WOMENS HEALTH, 2007, 3 (05) : 523 - 528
  • [8] Complete response after pertuzumab plus trastuzumab plus docetaxel in metastatic Her2-positive breast cancer patients: review of four cases
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 845 - 846
  • [9] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [10] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
12345